Results 151 to 160 of about 850,713 (297)

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Genome-wide association study and drought tolerance evaluation of a winter wheat association mapping panel

, 2015
Wahid Awad
openalex   +2 more sources

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Additional file 6: of Genome-wide association study reveals new loci for yield-related traits in Sichuan wheat germplasm under stripe rust stress

, 2019
Xueling Ye, Jian Li, Yukun Cheng, Fangjie Yao, Li Long, Yuqi Wang, Yu Wu, Jing Li, Jirui Wang, Qiantao Jiang, Houyang Kang, Wei Li, Pengfei Qi, Xiujin Lan, Jian Ma, Yaxi Liu, Yunfeng Jiang, Yuming Wei, Xianming Chen, Chunji Liu, Youliang Zheng, Guoyue Chen   +21 more
openalex   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

Molecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh   +8 more
wiley   +1 more source

Intracranial aneurysm genome-wide association study summary statistics 2020

, 2021
Mark K. Bakker, Jan H. Veldink, Ynte M. Ruigrok   +2 more
openalex   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer

, 2014
Þórunn Rafnar, Patrick Sulem, Guðmar Þorleifsson, Sita H. Vermeulen, Hannes Helgason, Jona Saemundsdottir, Sigurjón A. Guðjónsson, Ásgeir Sigurðsson, Simon Stacey, Jūlı́us Guðmundsson, Hrefna Johannsdottir, Kristín Alexíusdóttir, Vigdís Pétursdóttir, Sigfús Nikulásson, Guðmundur Geirsson, Þorvaldur Jónsson, Katja K.H. Aben, Anne J. Grotenhuis, Gerald W. Verhaegh, Aleksandra M. Dudek, J.A. Witjes, Antoine G. van der Heijden, Alina Vrieling, Tessel E. Galesloot, Ana De Juan, Angeles Panadero, Fernando Rivera, Carolyn D. Hurst, D. Timothy Bishop, Sei Chung Sak, Ananya Choudhury, Mark Teo, Cecilia Arici, Angela Carta, Elena Toninelli, Petra de Verdier, Péter Rudnai, Eugen Gurzău, Kvetoslava Koppová, Kirstin A. van der Keur, Irene Lurkin, Mieke Goossens, Eliane Kellen, Simonetta Guarrera, Alessia Russo, Rossana Critelli, Carlotta Sacerdote, Paolo Vineis, Clémentine Krucker, Maurice P. Zeegers, Holger Gerullis, Д Ю Овсянников, Frank Volkert, Jan G. Hengstler, Silvia Selinski, Ólafur Þ. Magnússon, Gísli Másson, Augustine Kong, Daníel F. Guðbjartsson, Annika Lindblom, Ellen C. Zwarthoff, Stefano Porru, Klaus Golka, Frank Buntinx, Giuseppe Matullo, Rajiv Kumar, José Mayordomo, D. Gunnar Steineck, Anne E. Kiltie, Eiríkur Jónsson, François Radvanyi, Margaret A. Knowles, Unnur Þorsteinsdóttir, Lambertus A. Kiemeney, Kāri Stefánsson   +74 more
openalex   +2 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source